Skip to main content
See who owns your news
Get Started
SubscribeLogin
Published • loading... • Updated

AbbVie (NYSE:ABBV) Given "Buy" Rating at Guggenheim

Summary by MarketBeat
Guggenheim reiterated a "buy" rating and set a $288.00 price target on shares of AbbVie in a report on Friday.

1 Articles

MarketBeatMarketBeat
Center

AbbVie (NYSE:ABBV) Given "Buy" Rating at Guggenheim

Guggenheim reiterated a "buy" rating and set a $288.00 price target on shares of AbbVie in a report on Friday.

·Sioux Falls, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MarketBeat broke the news in Sioux Falls, United States on Friday, October 9, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

AbbVie icon

AbbVie

North Chicago icon

North Chicago

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal